-
Analyst Prescribes Neutral Rating For Pfizer Shares
Thursday, July 20, 2017 - 9:57am | 298Read More...Previewing second-quarter results of Pfizer Inc. (NYSE: PFE), Credit Suisse prescribed a Neutral rating for the shares of the company, down from its previous Outperform rating. Pfizer is scheduled to release its second-quarter results at 7 a.m. ET on Aug. 1. Analysts led by Vamil Divan expect...
-
Pfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI
Friday, October 21, 2016 - 2:52pm | 336Read More...Investors of Pfizer Inc. (NYSE: PFE) failed to boost the sentiments after the company disclosed that its sNDA for prostate cancer drug XTANDI was granted approval by the FDA. The company applied sNDA to upgrade the product labeling for capsules of XTANDI to add new clinical data compared to...
-
Wedbush Previews Medivation's Q2 Earnings, Sees Takeout In Mid- To High-$60 Range
Tuesday, July 12, 2016 - 8:01am | 314Read More...Wedbush’s David M. Nierengarten believes that a likely takeout price for Medivation Inc (NASDAQ: MDVN) would be in the mid- to high-$60 per share range, including the probable realized value of any CVR for Talazoparib. Nierengarten reiterated an Outperform rating on the company, while raising...
-
Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 Takeout Price
Thursday, July 7, 2016 - 2:33pm | 462Read More...As multiple suitors line up to acquire Medivation Inc (NASDAQ: MDVN), BMO Capital said a winning bid will require an acceptable value for Talazoparib, likely a premium over the $410 million upfront payment to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). The Talazoparib Issue Last year, Medivation...
-
Medivation Advises Its Shareholders To Spurn Sanofi's Move To Replace Entire Board
Wednesday, May 25, 2016 - 9:48am | 444Read More...Medivation Inc (NASDAQ: MDVN) disclosed that it advised its stockholders to reject Sanofi SA (ADR) (NYSE: SNY)'s attempt to replace its entire board of directors with hand-picked nominees through a proposed consent solicitation. The company believes it was a strategy for Sanofi to make easy its...
-
Barclays Lays Out Its Sum-Of-The-Parts Analysis On Medivation, Boosts Target Price By $22
Friday, May 6, 2016 - 2:19pm | 297Read More...Barclays has raised the price target on the shares of Medivation Inc (NASDAQ: MDVN) to $70 from $48, driven by the increased visibility on duration gains and pipeline front. The sum-of-the-parts valuation by analyst Geoff Meacham, who has an Overweight rating on the stock, now assigns $55 for...
-
Medivation's Take-Out Price Raised To $68-$78 At Citi
Friday, May 6, 2016 - 9:48am | 328Read More...Citi’s Yigal Nochomovitz has raised the take-out range estimate for Medivation Inc (NASDAQ: MDVN) to $68–$78 to reflect the full value of Xtandi. Nochomovitz upgraded the rating on the company from Neutral to Buy, while raising the price target from $27 to $73. Take-Out Estimate The...
-
If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi's Bid
Friday, May 6, 2016 - 9:29am | 267Read More...Medivation Inc (NASDAQ: MDVN) reported its U.S. and ex-U.S. Xtandi sales for 1Q16 in line with the consensus. Brean Capital’s Jonathan Aschoff maintains a Buy rating on the company, with a price target of $61. Xtandi Outlook Growth in the underlying demand for Xtandi has continued, rising...
-
Stifel Lays Out 3 Scenarios For Medivation Takeover
Monday, May 2, 2016 - 1:49pm | 318Read More...Stifel analyst Thomas Shrader laid out three scenarios for Medivation Inc (NASDAQ: MDVN) takeover after the biopharma company rejected Sanofi SA (ADR) (NYSE: SNY)'s $52.50 acquisition bid. Shrader raised his target price on the stock by $14 to $66, which is also his minimum takeover price for...
-
Jefferies Lifts Target On Medivation To $52 From $39 As 'Xtandi Looking Better'
Monday, May 2, 2016 - 1:28pm | 388Read More...Jefferies raised the price target of Medivation Inc (NASDAQ: MDVN) shares to $52 from $39 after its survey showed "meaningful improvement" in the market for Xtandi on almost all fronts. The Physician Survey Jefferies conducted a physician survey "to gauge the outlook for Medivation's Xtandi given...
-
Here's What Medivation Said In Its Rejection Letter To Sanofi
Friday, April 29, 2016 - 1:38pm | 361Read More...Medivation Inc (NASDAQ: MDVN) disclosed on Friday a letter it has written to Sanofi SA (ADR) (NYSE: SNY) with regards to its acquisition offer to buy the company for $52.50 per share. Medivation started off by stating its Board of Directors unanimously rejected Sanofi's proposal to fully...
-
Leerink: Medivation Buyout 'Inevitable,' AstraZeneca And AbbVie Most Likely Buyers
Monday, April 25, 2016 - 9:51am | 324Read More...Leerink’s Geoffrey C. Porges believes that acquirer interest in Medivation Inc (NASDAQ: MDVN) and the appreciation in the stock valuation as “evidence of investors’ views that more value lies in the sale of the company vs. its independence.” Porges maintained a Market...
-
SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position
Wednesday, April 13, 2016 - 12:44pm | 623Read More...The M&A rumors continue to swirl around biotech firm Medivation Inc (NASDAQ: MDVN), and a SunTrust analyst has commented that the latest take-over chatter highlights the value of the company. A Bloomberg report said Medivation has rejected a take-out offer from Sanofi SA (ADR) (NYSE: SNY),...
-
Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price
Tuesday, March 29, 2016 - 9:18am | 189Read More...Shares of Medivation Inc (NASDAQ: MDVN) were trading lower by more than 6 percent heading into Tuesday's market open as the company's drug pricing have come under scrutiny by the U.S. Congress. According to ABC News, a group of U.S. lawmakers initiated a campaign to potentially lower the price of...
-
Medivation Up As Triple M&A Interest Rumor Circulates
Tuesday, March 22, 2016 - 10:47am | 292Read More...Medivation Inc (NASDAQ: MDVN) is up roughly 2 percent on Tuesday, trading at $37.68. According to the UK's financial outlet This Is Money, Medivation may be courting suitors. Among the names that have begun circulating as interested parties are AstraZeneca plc (ADR) (NYSE: AZN), Sanofi SA (ADR) (...
